MDX Medical Inc. (TSX.V: MDX) announced today it has hired Mr. Stewart Reid as VP Marketing & Communications. Mr. Reid will lead MDX's corporate communication and investor relations program. Mr. Reid will also be responsible for product marketing with an initial focus on the Company's NIRS (near-infrared spectrophotometry) urodynamics technology.


NIRS is a breakthrough in bladder care providing non-invasive monitoring in the diagnosis of urinary incontinence and bladder dysfunction. The World Health Organization estimates that bladder dysfunction and related urinary incontinence affects 200 million people worldwide with annual treatment costs estimated at USD $16 billion. This condition, when properly diagnosed and assessed, can be treated effectively.


Over the past 8 years Mr. Reid was an investment professional specializing in financing early stage technology companies and wealth management. Most recently Mr. Reid was the lead broker on the company's August 2005 $1.7 million financing. Previously, Mr. Reid had a successful 12 year career in the sales and marketing of high technology products and solutions with leading multi-national companies.


Barry Allen, President and CEO of MDX Medical stated "The addition of Mr. Reid will accelerate MDX's completion of its corporate objectives and technology milestones. Having worked with Mr. Reid in the past, I am confident his direct and relevant experience and knowledge in corporate finance and technology marketing will be a key addition to MDX and a real asset as we commercialize the NIRS technology."


MDX Medical announces that it has granted Mr. Reid incentive stock options to purchase 500,000 common shares at $0.16 per share for a five year period, pursuant to the Company's Stock Option Plan. The granting of these options is subject to acceptance for filing by the TSX Venture Exchange.


About MDX Medical:


MDX Medical Inc.'s focus is on the commercialization of novel, innovative and leading edge medical device technologies for improved diagnosis and treatment of prominent health disorders. The Company's business strategy is to acquire and commercialize high potential technologies that have reached the "proof of feasibility" or later stages of product development. For more information about MDX, please visit our website at: www.mdxmedical.com.


On behalf of the Board,


"Barry Allen"


President & CEO


MDX Medical Inc.


Certain information contained in this press release may be forward looking and is subject to unknown risks, which could cause actual results to differ materially from those, set forth or implied herein. Although the Company believes that the expectations reflected in such forward looking statements are reasonable, it can give no assurance that such expectations will prove correct.


The TSX Venture Exchange has not reviewed and does not accept


responsibility for the adequacy or accuracy of this release.


For further information: Stewart Reid, VP Marketing & Communications, Phone: (604) 638-0247, Email: stewartmreid@mdxmedical.com, http://www.mdxmedical.com